Globally Recognized Impact Investors Back Leyden Labs’ Mission to Transform Protection Against Respiratory Viruses with €40 Million Investment

LEIDEN, Netherlands--(BUSINESS WIRE)--Dutch biotech Leyden Laboratories B.V. (the “Company” or “Leyden Labs”) today announced a €40 million investment from the European Innovation Council (EIC) Fund, Invest-NL, Gates Foundation, ClavystBio, and others. The financing brings together a strong group of impact-focused investors from Europe, the United States, and Asia to support novel approaches that could better protect people worldwide against influenza and other respiratory viruses. Respiratory